← Alle mensen

RE

Rachel E Sanborn

6 publicaties

PubMed → Google Scholar →

Publicaties op Oncologisch.com

Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-smal...

European journal of cancer (Oxford, England : 1990) · 9 september 2025

A Multicenter Open-Label Gerandomiseerde Fase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase...

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025-02

Subcutaan versus IV amivantamab plus lazertinib bij EGFR-gemuteerd NSCLC: PALOMA-3

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 20 oktober 2024

Amivantamab plus chemotherapie bij EGFR exon 20 inserties NSCLC: PAPILLON fase III

The New England journal of medicine · 30 november 2023

Atezolizumab plus chemotherapie als eerstelijns bij niet-plaveiselcel NSCLC: IMpower132 fase III

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2021-04

Durvalumab plus tremelimumab bij niet-kleincellig longcarcinoom: veiligheid en werkzaamheid

The Lancet. Oncology · 2016-03